Cell line · CVCL_0371
Papers63
1 to 20 of 63
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Yes-Associated Protein Drives Helicobacter pylori-Induced Metaplastic Changes in Gastric Epithelium. | Cell Mol Gastroenterol Hepatol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The Role of NADPH Oxidase 4 in Neutrophil-Mediated Immune Escape in Gastric Cancer. | Int J Biol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Salinomycin as a death switch: how gastric cancer cells choose their demise. | Cell Death Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| GAL3ST1-Mediated Histone Tyrosine Sulfation Induced by Cancer-Associated Fibroblasts Promotes Gastric Cancer Metastasis. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| DS-3939a: A TA-MUC1-Directed Antibody-Drug Conjugate with Broad Antitumor Activity. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The transcriptomic fingerprint of cancer response to Tumor Treating Fields (TTFields). | Cell Death Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting PTBP3-Mediated Alternative Splicing of COX11 Induces Cuproptosis for Inhibiting Gastric Cancer Peritoneal Metastasis. | Adv Sci (Weinh) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Biological Activity of Peptide Fraction Derived from Hermetia illucens L. (Diptera: Stratiomyidae) Larvae Haemolymph on Gastric Cancer Cells. | Int J Mol Sci | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Immunomodulatory effects of trastuzumab deruxtecan through the cGAS-STING pathway in gastric cancer cells. | Cell Commun Signal | 2024 | Its Methods give the RRID and name the line | PubMed | |
| YAP-TEAD inhibition is associated with upregulation of an androgen receptor mediated transcription program providing therapeutic escape. | FEBS Open Bio | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Establishment of a novel small bowel adenocarcinoma cell line using patient‑derived xenografts, which produces CEA and CA19‑9. | Oncol Lett | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Proteome-based molecular subtyping and therapeutic target prediction in gastric cancer. | Mol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Targeting the receptor tyrosine kinase MerTK shows therapeutic value in gastric adenocarcinoma. | Cancer Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| KRAS activation in gastric cancer stem-like cells promotes tumor angiogenesis and metastasis. | BMC Cancer | 2023 | Its Methods give the RRID and name the line | Retracted | PubMed |
| RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations. | Cancer Discov | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Role of IL-6/STAT3 Axis in Resistance to Cisplatin in Gastric Cancers. | Biomedicines | 2023 | Its Methods give the RRID and name the line | PubMed | |
| ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell-mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models. | Cancer Res Commun | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| Cationic Channel TRPV2 Overexpression Promotes Resistance to Cisplatin-Induced Apoptosis in Gastric Cancer Cells. | Front Pharmacol | 2021 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0371/papers